Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
Medifocus Inc. Announces Closing of First Tranche of $3,540,000 Convertible Debenture Financing
Marketwire - Wed Dec 18, 8:17AM CST
Medifocus Inc. (OTCQX: MDFZF)(TSX VENTURE: MFS) announced today the initial closing of a non-brokered private placement of 354 units at a price of $10,000 per unit (the Units). The $3,540,000 is part of the Company's non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company expects to complete the remainder of the Offering on or before January 17, 2014.
Medifocus, Inc. Announces, VM Medical Center in Montreal Has Successfully Treated Its First Patient in Its Pivotal Phase III Clinical Trial for Breast Cancer Treatment
Marketwire Canada - Wed Dec 11, 9:13AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that VM Medical Center in Montreal, its Principal Investigational Site in Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study, has successfully treated its first patient enrolled. Dr. John R. Keyserlingk, MD is the Principal Investigator at the VM Medical Center in Montreal, Canada. The VM Medical Center is the largest non-public private breast center in Canada.
Medifocus Inc. Announces Record 294% Increase in Q2/FY 2014 Revenue
Marketwire Canada - Wed Dec 04, 8:21AM CST
Medifocus, Inc. (OTCQX: MDFZF), (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the use of focused microwave energy to treat cancer and other tumors, is pleased to announce its financial results for the three and six month periods of fiscal 2014 ending September 30, 2013.